Reaction
Rectal Cancer Metastatic reporting signals
As of the last recalculation, Rectal Cancer Metastatic appears in 342 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is PANITUMUMAB (PRR 180.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Panitumumab | 41 | 180.9 | 181.3 |
| Regorafenib | 22 | 123.2 | 123.4 |
| Trifluridine And Tipiracil | 16 | 95.2 | 95.3 |
| Oxaliplatin | 60 | 59.5 | 59.5 |
| Irinotecan Hydrochloride | 10 | 48.7 | 48.8 |
| Fluorouracil Cream, 0.5% | 50 | 46.6 | 46.6 |
| Leucovorin Calcium | 14 | 46.4 | 46.5 |
| Fluorouracil | 50 | 45.9 | 45.9 |
| Bevacizumab | 56 | 32.7 | 32.7 |
| Cetuximab | 12 | 24.1 | 24.1 |